Loading...
•
Jun 30, 2023
Maravai Q2 2023 Earnings Report
Reported a decrease in revenue due to reduced COVID-19 related demand and customer spending constraints, while focusing on expanding product portfolio and market leadership.
Key Takeaways
Maravai LifeSciences reported a 72% decrease in revenue for Q2 2023, totaling $68.9 million, driven by a significant decline in Nucleic Acid Production revenue due to lower COVID-19 related CleanCap demand. The company experienced a net loss of $(11.9) million and an Adjusted EBITDA of $9.1 million. Updated financial guidance for 2023 projects total revenue in the range of $300.0 million to $325.0 million.
Second quarter revenue was $68.9 million.
Net loss was $(11.9) million.
Adjusted EBITDA margin was 13.2%.
Completed leadership transition with Trey Martin as CEO effective July 27, 2023.
Revenue by Segment
Forward Guidance
Maravai projects total revenue for 2023 to be in the range of $300.0 million to $325.0 million. Adjusted EBITDA is expected to be in the range of $70.0 million to $80.0 million. Adjusted fully diluted EPS is projected to be between $0.04 and $0.08 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...